Forest Builds On Viibryd With Levomilnacipran NDA For Its “Middle” Antidepressant

Forest hopes the SNRI can follow the enantiomer blockbuster model. The application includes in vitro data showing that levomilnacipran has a greater potency for norepinephrine reuptake inhibition, without directly affecting the uptake of dopamine or other neurotransmitters.